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Abstract Greater use of evidence-based therapies has
improved outcomes for patients with acute coronary syn-
dromes (ACS) in recent decades. Consequently, more ACS
patients are surviving beyond 12 months; however, limited
data exist to guide treatment in these patients. Long-term
outcomes have not improved in non-ST-segment elevation
myocardial infarction (NSTEMI) patients at the same rate
seen in ST-segment elevation myocardial infarction pa-
tients, possibly reflecting NSTEMI patients’ more complex
clinical phenotype, including older age, greater burden of
comorbidities and higher likelihood of a previous myocar-
dial infarction (MI). This complexity impacts clinical deci-
sion-making, particularly in high-risk NSTEMI patients, in
whom risk–benefit assessments are problematical. This re-
view examines the need for more effective long-term man-
agement of NSTEMI patients who survive C12 months
after MI. Ongoing risk assessment using objective measures
of risk (for bleeding and ischemia) should be used in all post-
MI patients. While 12 months appears to be the optimal
duration of dual antiplatelet therapy for most patients, this
may not be the case for high-risk patients, and more research
is urgently needed in this population. A recent subgroup
analysis from the DAPT study in patients with or withoutMI
who had undergone coronary stenting (31 % presented with
MI; 53 % had NSTEMI) and the prospective PEGASUS-
TIMI 54 trial in patients with a priorMI and at least one other
risk factor (40 % had NSTEMI) demonstrated that long-
term dual antiplatelet therapy improved cardiovascular
outcomes but increased bleeding. Further studies will help
clarify the role of dual antiplatelet therapy in stable post-
NSTEMI patients.
Keywords Acute coronary syndromes  Dual antiplatelet
therapy  Non-ST-segment elevation myocardial infarction
Introduction
Approximately 50–75 % of patients experiencing an acute
coronary event in the US each year have a non-ST-segment
elevation myocardial infarction (NSTEMI) [1–3], and the
proportion of NSTEMI events is increasing [4]. Mortality
rates after myocardial infarction (MI) have decreased over
the last 20 years [3], but improvement in outcomes differs
between ST-segment elevation myocardial infarction
(STEMI) and NSTEMI patients. Compared with STEMI
patients, NSTEMI patients have lower short-term mortality
rates, and higher rates of long-term mortality, even after
adjustment for risk factors [2, 4]. One-year mortality rates
for STEMI patients have declined recently, but in NSTEMI
patients, the trend is inconsistent and less marked [3].
Registry data suggest that the 10-year survival rate after
NSTEMI is around 50 % [5].
Several years ago, the only interventional options for
acute coronary syndromes (ACS) were balloon angioplasty
or surgery, and post-percutaneous coronary intervention
(PCI) patients received warfarin. PCI provided only mod-
erate benefit [6], but the advent of coronary stents and more
potent antiplatelet agents have significantly improved
outcomes, such that PCI is now recommended for most
NSTEMI patients [7, 8]. Evidence-based therapy use,
during and after hospitalization, has increased over the past
several years in both STEMI and NSTEMI patients [3].
Yet, despite this increase and the associated improvement
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in outcomes after ACS, a significant residual risk, in the
short (up to 12 months) and long term (C3 years or
longer), for cardiovascular-related death remains [9].
A key question is why are long-term outcomes not im-
proving in NSTEMI patients as for STEMI patients? The
likely reason is that patients with NSTEMI tend to have a
more complex clinical phenotype. Compared with STEMI
patients, NSTEMI patients tend to be older, have more
comorbidities, are more likely to have an MI history, and to
experience recurrent ischemia after the acute event [2, 3].
Thus, clinical decision making is more complicated, par-
ticularly in high-risk NSTEMI patients, as risk–benefit
assessment is less straightforward. Poorer outcomes in
high-risk NSTEMI populations indicate the need for more
effective treatments. Clear evidence supports treatment
decisions in the acute and post-acute phase of ACS; how-
ever, data are limited to guide long-term management in
the growing population of patients who survive beyond
12 months after an event– many of whom are elderly and
have comorbidities.
This review examines the need for more effective
management; reviews the evidence and rationale for
treatment; identifies opportunities to improve outcomes;
and outlines recent research addressing unmet needs in
high-risk NSTEMI patients. Herein, ‘long term’ refers to
outcomes occurring C12 months after the initial ACS.
Current treatment recommendations for high-risk
patients
An urgent invasive strategy is generally preferred as initial
management in NSTEMI patients with refractory angina,
signs or symptoms of heart failure, and hemodynamic
instability [7]. Patients should undergo angiography with-
in 2 h of admission, with appropriate anti-ischemic,
antiplatelet, and anticoagulant therapy [7]. Urgent
catheterization is preferred in high-risk patients, who show
better outcomes with this approach versus delayed
catheterization [10]. Other high-risk NSTEMI patients
should undergo an early invasive strategy (within 24 h of
presentation) [7]. For in-hospital NSTEMI management,
currently recommended dual antiplatelet therapy incorpo-
rates aspirin with either clopidogrel or ticagrelor; ticagrelor
is preferred in patients undergoing early invasive or is-
chemia-guided therapy [7].
Previously, the American Heart Association/American
College of Cardiology (AHA/ACC) guidelines suggested
that any P2Y12 inhibitor could be considered in NSTEMI
patients, but the 2014 update [7] brings antiplatelet rec-
ommendations more in line with European guidelines.
European guidelines recommend ticagrelor for all patients
at moderate to high risk of ischemic events, regardless of
initial treatment strategy [8]. In Europe, prasugrel is rec-
ommended for P2Y12 inhibitor-naı¨ve patients with known
coronary anatomy who are proceeding to PCI, unless
contraindicated, or patients at high risk of bleeding [8].
Clopidogrel is recommended only for patients who cannot
receive ticagrelor or prasugrel [8].
The 2014 AHA/ACC NSTEMI guidelines emphasize
secondary prevention, including ongoing use of dual an-
tiplatelet therapy for post-hospital care [7]. Table 1 sum-
marizes the AHA/ACC recommendations for maintenance
dosing of antiplatelet agents. As with US guidelines,
European guidelines recommend treatment with a P2Y12
inhibitor for at least 12 months after the event [8].
All post-NSTEMI patients should receive beta-blockers
and statins long term, unless contraindicated [7]; patients
may also require medications to modify risk factors, such
as antihypertensive medications to achieve target blood
pressure, angiotensin-converting enzyme (ACE) inhibitors
for left ventricular dysfunction, and antihyperglycemic
agents to maintain HbA1c\7 % [7, 11].
Data supporting current recommendations
CHARISMA assessed clopidogrel plus aspirin in a high-
risk cohort of patients with established atherothrombotic
disease or at high risk of atherothrombosis [12]. Although
the group with risk factors did not necessarily derive
clinical benefit from dual antiplatelet therapy, those with
established disease did [12]. Therefore, a subanalysis of the
high-risk secondary prevention population was undertaken
[13]. These patients had prior MI (n = 3846), stroke
(n = 3245), or symptomatic peripheral arterial disease
(PAD) (n = 2838), and received clopidogrel or placebo,
plus aspirin, for a median of 27.6 months. Patients taking
clopidogrel plus aspirin had a significantly lower risk of
cardiovascular death, MI, or stroke (primary end point)
versus those receiving placebo plus aspirin (7.3 vs. 8.8 %;
hazard ratio [HR], 0.83 [95 % confidence interval (CI),
0.72–0.96]; p = 0.01). In prior MI cohort, the primary
composite end point occurred in 6.6 % of patients taking
clopidogrel plus aspirin versus 8.3 % of those taking
placebo plus aspirin (HR, 0.774 [95 % CI, 0.613–0.978];
p = 0.031). The benefit of dual antiplatelet therapy was not
seen in patients with established coronary artery disease
(CAD) without prior MI (Fig. 1) [13], implying that dual
antiplatelet therapy may provide a benefit in the post-MI
setting, even if initiated some time after the event.
Current recommendations do not provide clear clinical
guidance on the duration of dual antiplatelet therapy, or
whether the therapy duration depends on the patient’s risk
profile. Previous studies (including two randomized con-
trolled trials) showed no significant benefit in continuing
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dual antiplatelet therapy beyond 12 months in patients who
have undergone PCI and survive event-free for 1 year [14–
16]. A meta-analysis of the randomized data showed the
overall odds ratio for interrupting dual antiplatelet therapy
at 12 months versus continuing therapy was 1.18 (95 % CI,
0.61–2.29 [p = 0.62]) [15]. However, these studies were
underpowered, and did not necessarily enroll high-risk
patients [14, 15], so the question of whether or not ex-
tended treatment would be beneficial in high-risk patients
remains unanswered.
Impact of risk factors on outcomes
Optimal, evidence-based treatment after NSTEMI can only
reduce the risk of an event. Even optimally treated patients
face a residual risk of adverse cardiovascular outcomes due
to the underlying disease process, their general health, and
any comorbid conditions. So what constitutes ‘high risk’
after NSTEMI?
In the last decade, much has been learned about long-term
risk from registry studies, including GRACE, ACTION,
GTWG database, and CRUSADE registry data of NSTEMI
patients. These registries have contributed to the develop-
ment of a number of risk assessment tools (see below). A
consistent finding is that risk of adverse outcomes increases
with older age, male gender, diabetes, worse renal function,
renal failure, anemia, prior vascular disease/CAD, heart
failure (past or present), poor hemodynamics at presentation,
and clinical instability during ACS [17–20].
The Worcester Heart Attack Study (WHAS) investi-
gated long-term risk factors for mortality after discharge
specifically in NSTEMI patients, and found that older age,
male gender, longer hospital stay, history of stroke, heart
failure, or diabetes, and stroke or heart failure during
hospitalization all predicted long-term mortality [2]. Pa-
tients were studied for up to 5 years after the index event,
but analyses did not distinguish between risk factors for
death B12 versus[12 months [2].
Risk factors for 10-year mortality after NSTEMI in the
PRAIS-UK registry were age, ST depression or bundle
branch block on initial electrocardiogram (ECG), and a
history of heart failure [5]. However, this analysis was based
on UK NSTEMI patients in 1998 and 1999, and may not be
applicable to a contemporary NSTEMI population either in
the UK or elsewhere. EPICOR developed a risk score for
mortality in patients with STEMI (n = 4943) and non-ST-
elevation ACS (n = 5625) [21]. Twelve independent pre-
dictors of mortality were identified. In order of importance,
these were: age, lower ejection fraction, poorer EQ-5D
quality of life, elevated serum creatinine, in-hospital cardiac
complications, chronic obstructive pulmonary disease,
elevated blood glucose, male gender, no PCI/coronary artery
bypass grafting (CABG) after NSTE-ACS, low hemoglobin,
PAD, and on diuretics at discharge. However, the risk score
was based on 12-month mortality risk and may not be ap-
plicable to long-term outcomes.
Evidence suggests that biomarkers may be useful to help
identify high-risk patients after NSTEMI. Recent research
identified a number of biomarkers that enhance the accu-
racy of the GRACE risk assessment in NSTEMI patients,
including B-type natriuretic peptide [22], C-terminal va-
sopressin or copeptin [23], and growth differentiation fac-
tor-15 [24]. However, none of these biomarkers has yet
been adopted for risk assessment during clinical practice.
In summary, patients at high risk after NSTEMI are
likely to be of older age, men, and have cardiovascular (e.g.
heart failure, stroke) and non-cardiovascular (e.g. poor
Table 1 2014 AHA/ACC guidelines for use of antiplatelet agents in patients with invasively or non-invasively managed NSTEMI [7]
AHA/ACC recommendations COR LOE
Duration and maintenance dose of P2Y12 receptor inhibitor therapy in NSTEMI patients undergoing an early
invasive or ischemia-guided strategy
Clopidogrel 75 mg daily or ticagrelora 90 mg twice daily should be given for up to 12 months I B
It is reasonable to choose ticagrelor over clopidogrel IIa B
Duration and maintenance dose of P2Y12 receptor inhibitor therapy in NSTEMI patients who underwent
PCI and received a stent
Clopidogrel 75 mg daily, prasugrelb 10 mg daily, or ticagrelor 90 mg twice daily should be given
for at least 12 months
I B
It is reasonable to choose prasugrel over clopidogrel in patients who are not at high risk of bleeding complications IIa B
If the risk of morbidity from bleeding outweighs the anticipated benefits after stent implantation,
earlier discontinuation of P2Y12 receptor is reasonable
IIa C
Continuation of dual antiplatelet therapy beyond 12 months may be considered in patients undergoing stent implantation IIb C
COR class of recommendation, LOE level of evidence, NSTEMI non-ST-elevation myocardial infarction, PCI percutaneous coronary
intervention
a The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily
b Prasugrel should not be administered to patients with a prior history of stroke or transient ischemic attack (COR: III; LOE: B)
466 M. Cohen
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renal function, diabetes) comorbidities, and a poorer
quality of life than those at low risk.
Determination of risk
Several studies indicate that when established risk assess-
ment methods are not used, physicians tend to underesti-
mate risk in high-risk patients and overestimate risk in low-
risk patients [25]. Additionally, physicians tend to estimate
risk based on the intensity of treatment received during the
ACS [25, 26]. In particular, physicians underestimate risk
associated with age, and may view younger ACS patients
as having a more aggressive disease phenotype than older
patients, while underestimating the impact of age-associ-
ated accumulated coronary artery damage [26]. Therefore,
it is important that physicians use validated objective
measures of risk when assessing ACS patients.
Ischemic risk
Several risk-scoring tools evaluated the risk of subsequent
events in ACS patients, some of which can be used in
NSTEMI patients (Table 2) [17–19, 27–30]. These risk
scores, derived mainly from randomized controlled trials and
registry data, assess a patient’s short- to medium-term risk of
an adverse outcome (usually death and/or nonfatal MI).
While no risk tool is clearly superior to another, an
analysis by the UK National Institute for Health and
Clinical Excellence (NICE) suggests that the PURSUIT,
GRACE, and PREDICT tools provide better discrimina-
tion of mortality risk than the Thrombolysis in Myocar-
dial Infarction (TIMI) score [31]. TIMI and GRACE risk
scores are most commonly used, and available as online
calculators to simplify risk stratification in clinical prac-
tice [32].
Few of these tools were designed to assess long-term
risk (past 1 year). However, the GRACE score was a useful
predictor of death at 5 years in a mixed ACS population in
UK and Belgian GRACE registries [33], and at 10 years in
an NSTEMI cohort from the PRAIS UK registry [5].
The PREDICT tool was one of the few designed to
predict long-term outcomes, and has a better predictive
power for 2- or 6-year outcomes than for 30-day outcomes
[17]. However, PREDICT was developed in a mostly white
population, and is not specific for NSTEMI patients.
The SYNERGY tool was designed to assess 1-year
outcomes in patients surviving 30 days after the acute
event [30]. This tool may be particularly useful for the care
of long-term, post-hospitalization NSTEMI patients be-
cause it excludes risk factors that predict death during the
immediate post-ACS period.
Fig. 1 Kaplan–Meier curves for the primary composite end point of
cardiovascular death, MI, or stroke in subgroups of patients. a Patients
with prior MI in CHARISMA [13]; b Patients with prior MI in the
TRA2P-TIMI 50 trial [9]; c Patients with established coronary artery
disease who had not had an MI in CHARISMA [13]. ASA aspirin, CI
confidence interval, HR hazard ratio Panels a ? c are reprinted from J
Am Coll Cardiol 49 (19), Bhatt DL et al. ‘Patients with prior
myocardial infarction, stroke, or symptomatic peripheral arterial
disease in the CHARISMA trial.’ 1982–1988, copyright (2007), with
permission from Elsevier. Panel b is reprinted from The Lancet 380,
Scirica BM et al. ‘Vorapaxar for secondary prevention of thrombotic
events for patients with previous myocardial infarction: a prespecified
subgroup analysis of the TRA2P-TIMI 50 trial.’ 1317–1324,
copyright (2012) with permission from Elsevier

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Few tools exist to assess bleeding risk; the most widely
used was developed from the CRUSADE registry data of
NSTEMI patients, and is designed to assess risk of in-
hospital bleeding. The CRUSADE bleeding risk assess-
ment tool assigns a score based on the patient’s baseline
hematocrit, creatinine clearance, heart rate, gender, systolic
blood pressure, and presence of prior vascular disease,
congestive heart failure on presentation or diabetes mellitus
[34].
Another bleeding risk assessment tool was developed
from the ACTION-GTWG database [35], including STEMI
and NSTEMI patients. The ACTION-GTWG bleeding-risk
score is more complicated than CRUSADE, and includes
12 variables. It includes all of the variables in the CRU-
SADE risk tool (notwithstanding using hemoglobin instead
of hematocrit as a measure of anemia, and serum creatinine
instead of creatinine clearance for renal function), and also
includes body weight, warfarin use, and the presence and
type of ST changes on ECG [35]. This tool has been
validated for the prediction of major bleeding during hos-
pitalization, but no data are available on its use to predict
long-term bleeding.
Balancing the risk of ischemic versus bleeding events
Treatment selection in clinical practice must balance risk
of ischemic events with bleeding risk, which is difficult in
patients with multiple risk factors. Many risk factors for
ischemic events are the same as for bleeding events,
complicating decision making. Bleeding during hospital-
ization for NSTEMI is associated with a higher rate of
mortality in the first 30 days, 1 and 3 years after an event,
particularly in patients undergoing PCI [36]. This finding
may be partly explained by reduced use of dual antiplatelet
therapy at discharge in patients with a bleeding event
during hospitalization [36].
While bleeding may be a marker for a poor long-term
outcome, bleeding may not be causally related to outcome
[37]. In an analysis of CHARISMA (overall cohort) com-
paring patients who continued dual antiplatelet therapy and
those who discontinued, the rate of adverse outcomes, both
cardiovascular and bleeding events, over 28 months was
higher in thosewhodiscontinuedversus continued antiplatelet
therapy [38]. The increased bleeding rate among patients
discontinuing dual antiplatelet therapy was ascribed to pa-
tients who discontinued being more likely to have ischemic
risk factors, such as age and history of significant cardiovas-
cular disease; additionally, therapy may have been discon-
tinued because of prior bleeding [38].
For many high-risk patients, the risk-benefit profile is
not clear-cut, and should be considered on an individual
basis. For example, triple therapy (dual antiplatelet therapy
plus an oral anticoagulant) has been evaluated in ACS
patients. The ATLAS-ACS 2 TIMI-51 trial evaluated ri-
varoxaban (a selective factor Xa inhibitor) versus placebo
in ACS patients; all patients received aspirin plus a
thienopyridine [39]. Rivaroxaban reduced the rate of the
composite end point of MI, stroke, or death from cardio-
vascular causes versus placebo (8.9 vs. 10.7 %; HR, 0.84
[95 % CI, 0.74–0.96]; p = 0.008). However, versus
placebo, rivaroxaban also increased rates of major bleeding
not related to CABG (2.1 vs. 0.6 %, p\ 0.001) and in-
tracranial hemorrhage (0.6 vs. 0.2 %, p = 0.009), without
a significant increase in fatal bleeding (0.3 vs. 0.2 %,
p = 0.66) [39]. These data suggest that, in some patients,
the increased risk of major bleeding associated with triple
therapy may outweigh the benefit associated with a re-
duction in ischemic events [39], reinforcing the importance
of careful risk assessment in each patient based on clinical
and demographic characteristics.
Are patients being treated on the basis of risk?
Early data from the CRUSADE registry showed that dual
antiplatelet therapy was underutilized at discharge in
NSTEMI patients, and underutilization was greater in some
patient subgroups—those not undergoing PCI, those
aged[75 years, women, and Hispanic patients [40]. Fewer
than 50 % of eligible NSTEMI patients not undergoing PCI
received dual antiplatelet therapy in the CRUSADE reg-
istry in 2002/2003. This observation was also true in the
ACTION registry (2007–2010), which showed that 40.7 %
of NSTEMI patients in the US not undergoing PCI re-
ceived dual antiplatelet therapy [41]. This proportion is
lower than in NSTEMI patients not undergoing PCI re-
ported in the UK or Swedish registries during the same
period (70.6 and 48.8 %, respectively) [41]. However, the
overall rate of discharge antiplatelet use among NSTEMI
patients reported in the ACTION registry was around 74 %
between 2009 and 2012 [42].
An interesting finding in the recent analysis of ACTION
registry data (2009–2012) is the use of prasugrel in patients
in whom it is not indicated, or should be used with caution.
Prasugrel was used in 2 % of medically managed patients,
2 % of patients aged C75 years, and 5 % of patients
weighing\60 kg [42]. In addition, the highest rate of
prasugrel use was in patients with the lowest risk of is-
chemic or bleeding events (Fig. 2) [42], despite the fact
that evidence supports its use in individuals at high risk of
ischemic events.
Collectively, these data suggest that high-risk patients
may be undertreated after NSTEMI. Just as clinicians tend
to underestimate the ischemic risk in high-risk patients
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[25], it is possible that they may be overestimating the
risk of bleeding, as has been shown with the use of
antithrombotic therapy in high-risk atrial fibrillation pa-
tients [43]. Minimizing the risk of bleeding is important,
but undertreating may increase the risk of ischemic events.
Ischemia has irreversible effects on tissue and may have
long-term sequelae (e.g. heart failure, stroke-related dis-
ability), whereas bleeding can almost always be controlled
and, with the exception of intracerebral bleeding, does not
generally have long-lasting effects.
Treatment options: current knowledge and future
research
As more patients survive ACS, more evidence is needed to
support long-term treatment decisions, but few studies have
investigated outcomes and strategies for C12 months after
an event. The TRA2P-TIMI 50 trial investigated the effect
of the protease-activated receptor (PAR)-1 antagonist vo-
raxapar versus placebo on cardiovascular outcomes (com-
posite end point: cardiovascular death, MI, or stroke) in
patients with a history of atherothrombosis [44]. The patient
cohort included a large subgroup with a history of MI
(n = 17 779), but these patients had the qualifying MI be-
tween 2 weeks and 12 months prior to enrolment [9]. In
these patients with a history of MI (all of whom were taking
aspirin), voraxapar significantly reduced the 3-year risk of
the composite end point by 20 %, compared with placebo
(HR, 0.80 [95 % CI, 0.72–0.89]; p\ 0.0001), but at the
expense of a significant increase in the risk of moderate or
severe bleeding (HR, 1.61 [95 % CI, 1.31–1.97];
p\ 0.0001) [9]. When reviewed alongside the data from
CHARISMA, these data suggest that dual antiplatelet ther-
apy may be an effective strategy in stable post-MI patients,
and provides continued risk reduction when continued for
longer than 12 months (Fig. 1). However, the data are not
specific to NSTEMI patients and provide little guidance on
the effect of treatment started C12 months after MI.
The APOLLO study uses electronic medical record data
from patients who survive the first 12 months after an ACS
to evaluate their subsequent outcomes. This large-scale
study is being conducted in Sweden, England, France, and
the US, and will provide important information about
outcomes in a ‘real-world,’ unselected patient cohort rep-
resentative of clinical practice. Preliminary data suggested
that in the US, outcome rates over 3 years were worse than
those in the studied European countries. For example, the
all-cause mortality rate over 3 years was 30.2 % in the US,
compared with 20.1 % in Sweden, 14.3 % in France, and
13.7 % in the UK [45]. However, US patients also had
more comorbidities than patients in other countries, and the
difference was less marked (although significant vs. Swe-
den and UK) after adjustment for risk factors; adjusted all-
cause mortality was 12.8 % in the US, compared with
12.4 % in France, 11.2 % in Sweden, and 8.7 % in the UK
[45]. The DAPT study investigated the incidence of stent
thrombosis and major cardiovascular and cerebrovascular
events (a composite of death, MI, or stroke) in patients who
had received a stent [46]. In this randomized controlled
trial, 9961 patients received thienopyridine therapy
(clopidogrel or prasugrel) for 12 months, and were then
randomly assigned to either continue thienopyridine ther-
apy or receive placebo for 18 months. Rates of stent
thrombosis in the thienopyridine group were reduced ver-
sus placebo (0.4 vs. 1.4 %; HR, 0.29 [95 % CI, 0.17–0.48];
p\ 0.001), as were composite end-point events (4.3 vs.
5.9 %; HR, 0.71 [95 % CI, 0.59–0.85]; p\ 0.001) and MI
(2.1 vs. 4.1 %; HR, 0.47; p\ 0.001). However, all-cause
mortality was higher in the group that continued
thienopyridine treatment, compared with placebo (2 vs.
1.5 %; HR, 1.36 [95 % CI, 1.00–1.85]; p = 0.05). The
primary safety end point (rate of moderate or severe
bleeding) was higher in the thienopyridine group versus
placebo (2.5 vs. 1.6 %, p = 0.001). A recent subgroup
analysis from the DAPT study examined these same effi-
cacy and safety end points among patients undergoing
coronary stenting after presentation with or without an
acute MI (n = 3576 presented with MI [31 %]; 53 % had
NSTEMI) [47]. Compared with placebo, long-term
thienopyridine therapy statistically significantly reduced
the occurrence of stent thrombosis in both patient sub-
groups and significantly reduced major adverse cardio-
vascular and cerebrovascular events to a greater degree in
the MI group, but with a significantly higher occurrence of
bleeding in both subgroups (Table 3).
Fig. 2 Prasugrel use by mortality and bleeding risk in the NSTEMI
population of the ACTION registry [42]. Reproduced from Sherwood
MW et al. ‘Early clopidogrel versus prasugrel use among contem-
porary STEMI and NSTEMI patients in the US: insights from the
National Cardiovascular Data Registry. J Am Heart Assoc
2014;3:e000849, with permission from Wiley. 2014 The Authors.




Table 3 Summary of key efficacy and safety findings in randomized studies evaluating prolonged ([12 months) dual antiplatelet therapy (not








History of atherothrombosis; an
MI within previous
2–52 weeks
Vorapaxar (2.5 mg daily,
n = 8898) versus placebo
(n = 8881), both groups also
received aspirin
Significant reduction in 3-year
KM estimates for primary end
point (CV death, MI, or
stroke): 8.1 versus 9.7 %; HR,
0.80 (95 % CI, 0.72–0.89);
p\ 0.0001
Significant increase in 3-year
KM estimates for moderate or
severe bleeding: 3.4 versus
2.1 %; HR, 1.61 (95 % CI,
1.31–1.97); p\ 0.0001Median follow-up = 2.5 years
CHARISMA [13]
NCT00050817
Prior MI, ischemic stroke, or
PAD
Clopidogrel (75 mg daily,
n = 4735) versus placebo
(n = 4743), both groups also
received aspirin
Significant reduction in primary
end point (CV death, MI, or
stroke): 7.3 versus 8.8 %; HR,
0.83 (95 % CI, 0.72–0.96);
p = 0.01
No difference in rate of severe
bleeding: 1.7 versus 1.5 %;
HR, 1.12 (95 % CI,
0.81–1.53); p = 0.50
Significant increase in rate of
moderate bleeding: 2.0 versus
1.3 %; HR, 1.60 (95 % CI,
1.16–2.20); p = 0.004
Median follow-
up = 27.6 months
DAPT [46]
NCT00977938
Had a coronary stent procedure
(drug-eluting stent only)
After 12 months of clopidogrel
or prasugrel plus aspirin,
patients either continued on
the thienopyridine (n = 5020)
or received placebo
(n = 4941) for another
18 months
Significant reduction in rates of:
stent thrombosis (0.4 versus
1.4 %; HR, 0.29 [95 % CI,
0.17–0.48]; p\ 0.001); major
adverse CV and
cerebrovascular events (4.3
versus 5.9 %; HR, 0.71 [95 %
CI, 0.59–0.85]; p\ 0.001);
MI (2.1 versus 4.1 %; HR,
0.47 [95 CI: 0.37–0.61];
p\ 0.001)
Higher rate of all-cause
mortality (2 versus 1.5 %;
HR, 1.36 [95 % CI,
1.00–1.85]; p = 0.05)
Significant increase in rate of
GUSTO moderate or severe





Had a coronary stent procedure
(drug-eluting or bare-metal
stents) following presentation
with acute MI (n = 3576) or
without evidence of MI
(n = 8072)
After 12 months of clopidogrel
or prasugrel plus aspirin,
patients either continued on
the thienopyridine (n = 5862)
or received placebo
(n = 5786) for another
18 months
Significant reduction in rates of:
stent thrombosis (MI group:
0.5 versus 1.9 %; HR, 0.27
[95 % CI, 0.13–0.57];
p\ 0.001; no MI group: 0.4
versus 1.1 %; HR, 0.33 [95 %
CI, 0.18–0.60]; p\ 0.001);
major adverse CV and
cerebrovascular events (MI
group: 3.9 versus 6.8 %; HR,
0.56 [95 % CI, 0.42–0.76];
p\ 0.001)
Significant increase in rate of
GUSTO moderate or severe
bleeding (MI group: 1.9
versus 0.8 %; HR, 2.38 [95 %
CI, 1.28–4.43]; p = 0.005; no
MI group: 2.6 versus 1.7 %;
HR, 1.53 [95 % CI,
1.12–2.08]; p = 0.007)
No significant reduction in rate
of major adverse CV and
cerebrovascular events in no
MI group (4.4 versus 5.3 %;
HR, 0.83 [95 % CI,




Had a coronary stent procedure
(drug-eluting stent)
Patients randomized to either
6 months (n = 912) or
24 months (n = 910) of dual
antiplatelet therapy post-stent,
i.e. aspirin plus clopidogrel
(75 mg/day) or prasugrel
(60 mg/day) or ticagrelor
(90 mg twice daily)
No significant difference in
primary end point (death, MI,
target lesion
revascularization, stroke, and
major bleeding at 12 months
post-stent): 1.6 versus 1.5 %;
HR, 1.072 (95 % CI,
0.517–2.221); p = 0.85
Non-inferiority demonstrated
for 6- versus 12-month
treatment; absolute risk
difference 0.11 % (95 %
CI, -1.04–1.26); p for non-
inferiority = 0.0002
There were no significant
differences in bleeding
complications between the 6-
and 24-month groups: Major
bleeding occurred in only 3
(0.3 %) patients in the
24-month group (0 patients in
6-month group; HR, N/A);
minor bleeding (0.5 versus
0.4 %; HR, 1.247 [95 % CI,
0.335–4.643]; p = 0.74
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The potential for shortening the duration of dual anti-
platelet therapy in patients following drug-eluting stent-PCI
was evaluated in the ISAR-SAFE trial [48]. The trial results
showed that the primary composite end point (death, MI,
stent thrombosis, stroke or TIMI major bleeding) did not
differ between the group treated for 6 versus 12 months
(1.5 vs. 1.6 %, D -0.1 %, [1-sided 95 % CI, 0.5 %],
Pnoninferiority\ 0.001). A trend toward lower rates of bleed-
ing was observed in the group receiving 6 versus 12 months
of dual antiplatelet therapy. Similar findings were observed
in the ITALIC/ITALIC? trial, which reported that for pa-
tients who respond well to aspirin, 6 months is non-inferior
to 24 months of dual antiplatelet therapy for the composite
primary end point of death, MI, target lesion revascular-
ization, stroke, and major bleeding [49].
The multinational PEGASUS-TIMI 54 trial prospec-
tively investigated the effect of aspirin and ticagrelor on
outcomes in patients who had an MI 1–3 years previously
[50, 51]. This trial included 21,162 high-risk patients, all
currently taking low-dose aspirin (75–150 mg/day). As
well as a history of MI, patients had at least one of the
following risk factors: age C65 years, diabetes, a second
prior MI, multivessel CAD that included C50 % occlusion
in 2 or more coronary arteries, or chronic renal dysfunc-
tion. Patients were randomized 1:1:1 to placebo, ticagrelor
90 mg twice daily, or ticagrelor 60 mg twice daily. Median
follow-up was 33 months. Both ticagrelor doses sig-
nificantly reduced the primary efficacy end point (com-
posite of cardiovascular death, MI, or stroke), compared
with placebo. At 3 years, the Kaplan–Meier rates were
7.85 % (ticagrelor 90 mg), 7.77 % (ticagrelor 60 mg), and
9.04 % (placebo); ticagrelor 90 mg: HR, 0.85 (95 % CI,
0.75–0.96]; p = 0.008; ticagrelor 60 mg: HR, 0.84 (95 %
CI, 0.74–0.95]; p = 0.004. Rates of TIMI major bleeding
(primary safety end point) were higher with ticagrelor
(90 mg: 2.60 %; 60 mg: 2.30 %) versus placebo (1.06 %;
p\ 0.001 for each ticagrelor dose) [50]. The PEGASUS-
TIMI 54 data demonstrate the potential benefit of dual
antiplatelet therapy (ticagrelor and aspirin) beyond
12 months in high-risk, post-MI patients. Although this
trial was not specific for patients with NSTEMI, at base-
line, 40.3 % of the overall patients had NSTEMI.
Of the five randomized studies evaluating prolonged
([12 months) dual antiplatelet therapy, four studies (in-
cluding one subgroup analysis) demonstrated significant
clinical benefit (reduction in the primary efficacy end
point) with extending treatment, compared with controls.
Although in four studies, prolonged treatment resulted in
increased bleeding (Table 3). None of these trials were
specific for patients with NSTEMI, thus highlighting the
need for further research. Subanalyses of NSTEMI patients
in PEGASUS-TIMI 54, and more prospective studies in
high-risk NSTEMI patients, will advance our understand-
ing of long-term management of these patients.
Conclusions
There are currently limited data to guide clinical decision
making around optimal secondary preventive therapies in
NSTEMI patients who survive 12 months or more after
MI. While 12 months appears to be the optimal duration of
dual antiplatelet therapy for most patients, this may not be
the case for high-risk patients. Ongoing risk assessment
(for bleeding and ischemia) is important in all post-MI
patients, and clinicians should use objective measures of
assessment whenever possible to avoid over- or under-es-
timating future risk. Physicians also need to regularly
assess the risks and benefits of all therapies to suit the









History of MI 1–3 years
previously, at least one of the
following risk factors:
age C 65 years, diabetes, a
second prior MI, multivessel
CAD that included C50 %
occlusion in 2 or more
coronary arteries, or chronic
renal dysfunction
Three groups: ticagrelor
(90 mg twice daily
[n = 7050], or 60 mg twice
daily [n = 7045]) and
placebo (n = 7067); all
groups also received aspirin
Significant reduction in 3-year
KM estimates for primary end
point (CV death, MI, or
stroke): 7.85 % (90 mg
ticagrelor; HR, 0.85 [95 % CI,
0.75–0.96]; p = 0.008),
7.77 % (60 mg ticagrelor;
HR, 0.84 [95 % CI,
0.74–0.95]; p = 0.004), and
9.04 % (placebo)
Rates of TIMI major bleeding
were higher with ticagrelor
(90 mg: 2.60 %; 60 mg:
2.30 %) versus placebo
(1.06 %; p\ 0.001 for each
ticagrelor dose)
40.3 % of the overall patients
had NSTEMI
Median follow-up: 33 months
CAD coronary artery disease, CI confidence interval, CV cardiovascular, GUSTO Global Utilization of Streptokinase and TPA for Occluded
Arteries, HR hazard ratio, KM Kaplan–Meier, MI myocardial infarction, N/A not applicable, NSTEMI non-ST-segment elevation myocardial
infarction, PAD peripheral arterial disease, TIMI Thrombolysis in Myocardial Infarction
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years following ACS. More research is urgently needed to
help guide therapeutic decision making during long-term
management of complex patients after NSTEMI.
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